During the past decade, Fujian Cancer Hospital conducted 195 clinical trials. In the 10-year time frame, 195 clinical trials started and 22 clinical trials were completed, i.e. on average, 11.3% percent of trials that started reached the finish line to date. In the past 5 years, 129 clinical trials started and 13 clinical trials were completed. i.e. 10.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fujian Cancer Hospital" #1 sponsor was "Hoffmann-La Roche" with 22 trials, followed by "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 19 trials sponsored, "BeiGene" with 15 trials sponsored, "Fujian Cancer Hospital" with 13 trials sponsored and "Shanghai Junshi Bioscience Co., Ltd." with 13 trials sponsored. Other sponsors include 152 different institutions and companies that sponsored additional 93 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fujian Cancer Hospital" #1 collaborator was "West China Hospital" with 5 trials as a collaborator, "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 4 trials as a collaborator, "Fujian Cancer Hospital" with 4 trials as a collaborator, "Guangdong Provincial People's Hospital" with 4 trials as a collaborator and "Nanfang Hospital of Southern Medical University" with 4 trials as a collaborator. Other collaborators include 141 different institutions and companies that were collaborators in the rest 123 trials.

According to Clinical.Site data, the most researched conditions in "Fujian Cancer Hospital" are "Gastric Cancer" (10 trials), "Non-small Cell Lung Cancer" (8 trials), "Nasopharyngeal Carcinoma" (6 trials), "Non-Small Cell Lung Cancer" (6 trials) and "Breast Cancer" (5 trials). Many other conditions were trialed in "Fujian Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Fujian Cancer Hospital" are "Drug" (195 trials), "Biological" (14 trials), "Procedure" (14 trials), "Other" (12 trials) and "Radiation" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (37 trials), "Cisplatin" (17 trials), "Tislelizumab" (13 trials), "Atezolizumab" (12 trials) and "Anlotinib" (9 trials). Other intervention names were less common.

The vast majority of trials in "Fujian Cancer Hospital" are 214 trials for "All" genders, 17 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 129 active trials in "Fujian Cancer Hospital". 10 are not yet recruiting, 76 are recruiting, 40 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 46 completed trials in Fujian Cancer Hospital, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Fujian Cancer Hospital, 26 "Phase 1" clinical trials were conducted, 84 "Phase 2" clinical trials and 97 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 17 trials that are defined as “Not Applicable".

Fujian Cancer Hospital has several departments that took part in Clinical trials: "the Department of Cardiovascular Surgery" - 3 trials